An Ultra High Performance Liquid Chromatography-High Resolution Mass Spectrometry Metabolomics and Lipidomics Study of Stool from Transgenic Parkinson’s Disease Mice Following Immunotherapy

Congratulations Drs. Okun and Vedam-Mai. on the publication of “An Ultra High Performance Liquid Chromatography-High Resolution Mass Spectrometry Metabolomics and Lipidomics Study of Stool from Transgenic Parkinson’s Disease Mice Following Immunotherapy,” in the November issue of the Journal of Proteome Research.

Abstract

Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the brain as well as degeneration of motor and non-motor circuitry. The cause of neuronal death is currently unknown, although chronic neuroinflammation, aggregated α-synuclein, mitochondrial dysfunction and oxidative stress have all been implicated. Gliosis has been shown to exacerbate neuroinflammation via secretion of pro-inflammatory cytokines, and there is a subse-quent infiltration of T lymphocytes (T-cells), into the brain of PD patients. Using liquid chromatography-high resolution mass spectrometry (LC-HRMS), we have observed metabolomic changes in stool samples, thought to be associated with the potential disease-modifying effect of an immunotherapy administered to transgenic Parkinsonian (A53T) mice.

from Department of Neurology » College of Medicine » University of Florida https://ift.tt/33gziYI